Skip to main content
GKOS
NYSE Industrial Applications And Services

Glaukos Q2 Sales Surge 50%, Guidance Raised to $700M on iDose TR and Epioxa Momentum

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$178
Mkt Cap
$9.495B
52W Low
$73.16
52W High
$166
52W Position info
143% above low
Off High info
at 52W high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (3.0× avg).

Summary

Glaukos reported Q2 2026 net sales of $185.6 million, up 50% year-over-year, and raised full-year guidance to $680-$700 million. The beat was fueled by accelerating adoption of iDose TR and the initial launch of Epioxa.


Key Events · Earnings and Guidance · GKOS

  • Record Q2 Revenue, +50% YoY

    Net sales reached $185.6 million, with U.S. glaucoma up 64% to $118.5 million. iDose TR contributed ~$74 million and Epioxa added ~$11 million in its first full quarter.

  • Full-Year Guidance Raised to $680M-$700M

    Management lifted the 2026 revenue outlook from $620M-$635M, reflecting strong momentum in iDose TR adoption and Epioxa launch progress.

  • Gross Margin Expansion

    Non-GAAP gross margin improved to ~85% from ~83% a year ago, driven by favorable product mix and operating leverage.

  • Strong Balance Sheet

    Cash and short-term investments totaled $289.3 million with no debt, providing ample runway for continued R&D and commercial investments.


Analysis · GKOS · Industrial Applications And Services

Glaukos delivered a standout quarter with net sales jumping 50% to $185.6 million, driven by 64% growth in U.S. glaucoma sales. The company raised its full-year revenue outlook by $65 million at the midpoint, signaling confidence in the commercial launches of iDose TR and Epioxa. Gross margins expanded to 85% on a non-GAAP basis, and the balance sheet remains debt-free with $289 million in cash. This earnings beat and guidance raise materially improve the growth trajectory and de-risk the path to profitability.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GKOS was trading at $178.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $166.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GKOS - Latest Insights

GKOS
Oct 28, 2026, 5:22 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $215.00
Real-time Price: $237.31 info
Change: +$22.31 (+10%) info
Market Cap: $14.048B info
GKOS
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $196.05
Real-time Price: $237.31 info
Change: +$41.26 (+21%) info
Market Cap: $14.048B info
GKOS
Oct 28, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $181.43
Real-time Price: $237.31 info
Change: +$55.88 (+31%) info
Market Cap: $14.048B info
GKOS
Oct 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $161.29
Real-time Price: $237.31 info
Change: +$76.02 (+47%) info
Market Cap: $14.048B info
GKOS
Oct 08, 2026, 11:09 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $153.16
Real-time Price: $237.31 info
Change: +$84.16 (+55%) info
Market Cap: $14.048B info